ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 0726 • ACR Convergence 2021

    Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm

    Robert Fountaine1, Robert Dworkin2, Anne Hickman1, Glenn Pixton3, Ed Whalen4, Christine West1 and Kenneth Verburg1, 1Pfizer Inc., Groton, CT, 2University of Rochester, Rochester, NY, 3Pfizer Inc., Morrisville, NC, 4Pfizer Inc., New York, NY

    Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…
  • Abstract Number: 1273 • ACR Convergence 2021

    A 12-week Aerobic Exercise Training Program in Women with Systemic Lupus Erythematosus (SLE) Improves Fatigue, Mitochondrial Dysfunction and Associated Interferon Gene Signature

    Sarfaraz Hasni1, Marquis Chapman2, Rebekah Feng1, Anam Ahmad1, Sarthak Gupta3, Mohammad Naqi1, Adam Munday1, Shajia Lu1, Massimo Gadina2, Zerai Manna1, Xiaobai Li4, Yinghui Shi1, Kalyani Mishra-Thakur1, Michael Davis5, Jun Chu3, Elaine Poncio6, Yenealem Temesgen-Oyelakin7, Jonathan Martinez1, Zoe Morris1, Isabel Ochoa6, Shuichiro Nakabo8, Bart Drinkard1, Gayle McCrossin1, Marybeth Stockman1, Mariana Kaplan1, Leorey Saligan1, Randall Keyser9, Leighton Chan1 and Lisa Chin1, 1National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4Clinical Center, National Institutes of Health, Bethesda, MD, 5NIAMS, Bethesda, MD, 6NIH/NIAMS, Bethesda, MD, 7National Institutes of Health (NIH), Bethesda, MD, 8NIAMS/NIH, Bethesda, MD, 9George Mason University, Bethesda

    Background/Purpose: Fatigue in SLE patients is ubiquitous and is reported as one of the most debilitating symptoms. Yet mechanisms underlying the pathophysiology of SLE-related fatigue…
  • Abstract Number: 1502 • ACR Convergence 2021

    Longitudinal Changes in B Cell Subsets in Patients in the Mesenchymal Stromal Cell Trial in Lupus: Analysis of the First Cohort

    Diane Kamen1, S Sam Lim2, Scott Jenks3, Regina Bugrovosky3, Aisha Hill3, Chungwen Wei3, Cristina Drenkard3, Kenneth Kalunian4, Ummara Shah5, Mariko Ishimori6, Rosalind Ramsey-Goldman7, Saira Sheikh8, Mary Alison Mahieu7, Daniel Wallace9, Ellen Goldmuntz10 and Gary Gilkeson1, 1Medical University of South Carolina, Charleston, SC, 2Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 3Emory University, Atlanta, GA, 4UC San Diego, La Jolla, CA, 5University of Rochester, Rochester, NY, 6Cedars-Sinai Health System, Los Angeles, CA, 7Northwestern University, Chicago, IL, 8University of North Carolina, Chapel Hill, NC, 9Attune Health, Beverly Hills, CA, 10National Institutes of Health, Bethesda, MD

    Background/Purpose: Recent advances allow expanded identification of B cell subtypes of pathogenic potential in lupus. Of particular interest are IgD- CD27- double negative (DN2) B…
  • Abstract Number: 1733 • ACR Convergence 2021

    Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria

    Martin Aringer1, Ian N. Bruce2, Richard Furie3, Eric Morand4, Emmanuelle Maho5, Catharina Lindholm6 and Raj Tummala7, 1University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, 2University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 4Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 7BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD

    Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…
  • Abstract Number: 1772 • ACR Convergence 2021

    Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial

    Antoine Enfrein1, Beatrice Clemenceau2, Soraya Saiagh3, Céline Bressollette4, Zahir Amoura5, Henri Vie2 and Mohamed Hamidou1, 1Médecine interne, CHU de Nantes, Nantes, France, 2Inserm U1232, Université de Nantes, Nantes, France, 3Unité de Thérapie Cellulaire et Génique, CHU de Nantes, Nantes, France, 4Laboratoire de Virologie, CHU de Nantes, Nantes, France, 5Médecine interne, Hôpital Pitié Salpêtrière, AP-HP, Paris, France

    Background/Purpose: Epstein-Barr Virus (EBV) has been suggested as a potential environmental factor in systemic lupus erythematosus (SLE) onset and disease activity. Here, we report the…
  • Abstract Number: 1940 • ACR Convergence 2021

    Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Jeffrey Curtis1, Kunihiro Yamaoka2, Yi-Hsing Chen3, Levent M Gunay4, Naonobu Sugiyama5, Carol A Connell6, Cunshan Wang6, Joseph Wu6, Sujatha Menon6, Ivana Vranic7 and Juan J Gomez-Reino8, 1Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 2School of Medicine, Department of Rheumatology and Infectious Diseases, Kitasato University, Sagamihara, Japan, 3Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 4Pfizer Inc, Istanbul, Turkey, 5Pfizer Japan Inc, Tokyo, Japan, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, Tadworth, Surrey, United Kingdom, 8Hospital Clínico Universitario, Santiago de Compostela, Spain

    Background/Purpose: ORAL Surveillance (NCT02092467) was a post-authorization safety study to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based on observed increases in…
  • Abstract Number: 0226 • ACR Convergence 2021

    High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial

    Bardur Sigurgeirsson1, John Browning2, Stephen Tyring3, Jacek Szepietowski4, Raquel Rivera‐Díaz5, Isaak Effendy6, Deborah Keefe7, Gerard Bruin8, Bertrand Paguet9, Rong Fu10, Isabelle Hampele9 and Maximilian Reinhardt9, 1University of Iceland, Reykjavík, Iceland, 2Texas Dermatology and Laser Specialists, Texas, TX, 3Center for Clinical Studies, Texas, 4Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Departrment of Dermatology and Allergology, University Hospital of Bielefeld, Bielefeld, Germany, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Institutes for Biomedical Research, Basel, Switzerland, 9Novartis Pharma AG, Basel, Switzerland, 10Novartis Institutes of for Biomedical Research, Shanghai, China (People's Republic)

    Background/Purpose: The MATURE study investigated administration of 300 mg secukinumab (SEC) using a 2 mL autoinjector (AI) device. The objective of this study was to…
  • Abstract Number: 0828 • ACR Convergence 2021

    Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study

    Roy Fleischmann1, Eduardo Mysler2, Louis Bessette3, Charles Peterfy4, Patrick DUREZ5, Yoshiya Tanaka6, Jerzy Swierkot7, Nasser Khan8, Xianwei Bu9, Yihan Li9 and In-Ho Song8, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Organización Medica de Investigación, Rheumatology, Buenos Aires, Argentina, 3Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 4Spire Sciences, Inc., Boca Raton, FL, 5Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, 6University of Occupational and Environmental Health, Kitakyushu, Japan, 7Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, 8AbbVie Inc., North Chicago, IL, 9AbbVie Inc., North Chicago

    Background/Purpose: In the SELECT-COMPARE study, the Janus kinase inhibitor, upadacitinib (UPA), demonstrated significant improvement in the signs and symptoms of rheumatoid arthritis (RA) when administered…
  • Abstract Number: 1329 • ACR Convergence 2021

    Guselkumab (TREMFYA®) Maintains Resolution of Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Results Through 2 Years from a Phase 3 Study

    Proton Rahman1, Iain McInnes2, Atul Deodhar3, Georg Schett4, Philip Mease5, May Shawi6, Daniel Cua7, Jonathan Sherlock8, Alexa Kollmeier9, Xie Xu7, Yusang Jiang7, Shihong Sheng7, Christopher Ritchlin10 and Dennis McGonagle11, 1Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 2University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 3Oregon Health & Science University, Portland, OR, 4Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, 5Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 6Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 7Janssen Research & Development, LLC, Spring House, PA, 8Janssen Research & Development, LLC and University of Oxford, Spring House, PA, 9Janssen Research & Development, LLC, La Jolla, CA, 10Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, 11University of Leeds, Leeds, United Kingdom

    Background/Purpose: Guselkumab (GUS), a selective inhibitor of IL-23, significantly improved the diverse manifestations of active psoriatic arthritis (PsA), including dactylitis and enthesitis, in the DISCOVER…
  • Abstract Number: 1553 • ACR Convergence 2021

    Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up

    Lauren He1, Garth Strohbehn2 and Pankti Reid3, 1University of Chicago, Chicago, IL, 2VA Ann Arbor Center for Clinical Management and Research, Chicago, IL, 3University of Chicago Medical Center, Chicago, IL

    Background/Purpose: Tocilizumab (TCZ) for treatment of severe coronavirus disease 2019 (COVID-19) pneumonia decreases the probability of progression to invasive mechanical ventilation (CORIMUNO-TOCI) or death (REMAP-CAP,…
  • Abstract Number: 1734 • ACR Convergence 2021

    Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study

    Nadia Tchao1, Hamid Amouzadeh2, Nandita Sarkar1, Vincent Chow2, Xuguang Hu1, Mark Kroenke2, Hui Wang2, Rong Zhang2, Kevin Gorski1, Richard Furie3, Alan Kivitz4 and Stanley Cohen5, 1Amgen Inc., South San Francisco, CA, 2Amgen Inc., Thousand Oaks, CA, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Altoona Center for Clinical Research, Duncansville, PA, 5Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE. Efavaleukin alfa…
  • Abstract Number: 1773 • ACR Convergence 2021

    Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials

    Joris Diels1, Pushpike Thilakarathne2, Agata Schubert3, Fareen Hassan4, Steven Peterson5 and Wim Noël1, 1Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, 2JanssenCilag Ltd, HEMAR Department, Beerse, Belgium, 3Janssen-Cilag Poland, HEMAR Department, Warsaw, Poland, 4Janssen-Cilag Ltd, HEMAR Department, High Wycombe, United Kingdom, 5Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ

    Background/Purpose: Guselkumab is an anti-interleukin (IL)-23 monoclonal antibody recently approved for the treatment of psoriatic arthritis (PsA). In two large Phase III trials of patients…
  • Abstract Number: 1941 • ACR Convergence 2021

    The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Christina Charles-Schoeman1, Roy Fleischmann2, Eduardo Mysler3, Maria Greenwald4, Cunshan Wang5, All-shine Chen5, Carol A Connell5, John C Woolcott6, Sujatha Menon5, Yan Chen7, Kristen Lee7 and Zoltan Szekanecz8, 1Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 2Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 3Organización Médica de Investigación, Buenos Aires, Argentina, 4Desert Medical Advances, Palm Desert, CA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, New York, NY, 8Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary

    Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
  • Abstract Number: 0249 • ACR Convergence 2021

    Open-label, Long-term (10-year) Study of the Safety of Etanercept in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis

    Jelena Vojinović1, Joke Dehoorne2, Violeta Panaviene3, Gordana Susic4, Gerd Horneff5, Valda Stanevicha6, Katarzyna Kobusinska7, Zbigniew Zuber8, Bogna Dobrzyniecka9, Jonathan Akikusa10, Tadej Avcin11, Alberto Martini12, Cecilia Borlenghi13, Edmund Arthur14, Svitlana Tatulych15, Chuanbo Zang16, Bonnie Vlahos16 and Nicolino Ruperto17, 1Paediatric Rheumatology International Trials Organisation (PRINTO), Nis, Serbia, 2Paediatric Rheumatology International Trials Organisation (PRINTO), Gent, Belgium, 3Paediatric Rheumatology International Trials Organisation (PRINTO), Vilnius, Lithuania, 4Paediatric Rheumatology International Trials Organisation (PRINTO), Belgrade, Serbia, 5Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, 6Paediatric Rheumatology International Trials Organisation (PRINTO), Riga, Latvia, 7Paediatric Rheumatology International Trials Organisation (PRINTO), Bydgoszcz, Poland, 8Paediatric Rheumatology International Trials Organisation (PRINTO), Lodz, Poland, 9Paediatric Rheumatology International Trials Organisation (PRINTO), Warsaw, Poland, 10Paediatric Rheumatology International Trials Organisation (PRINTO), Melbourne, Australia, 11Paediatric Rheumatology International Trials Organisation (PRINTO), Ljubljana, Slovenia, 12Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 13Pfizer, Buenos Aires, Argentina, Buenos Aires, Argentina, 14Pfizer, Peapack, NJ, 15Pfizer, Groton, CT, 16Pfizer, Collegeville, PA, 17IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy

    Background/Purpose: CLIPPER2 was an 8-year, open-label extension of the phase 3b, multicenter, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in the…
  • Abstract Number: 0837 • ACR Convergence 2021

    Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial

    Peter Nash1, Arthur Kavanaugh2, Maya Buch3, Bernard Combe4, Louis Bessette5, In-Ho Song6, Tim Shaw7, Yanna Song6, Jessica Suboticki6 and Roy Fleischmann8, 1Griffith University, Brisbane, Australia, 2University of California San Diego, La Jolla, CA, 3University of Leeds, Leeds, United Kingdom, 4CHU Montpellier Montpellier University, Montpellier, France, 5Laval University, Québec City, QC, Canada, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., North Chicago, 8Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) or low disease activity (LDA).1,2 A greater proportion…
  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology